Clinical Trials Logo
NCT number NCT01525589
Study type Interventional
Source PharmaMar
Contact Cristian Fernández, MD
Email clinicaltrials@pharmamar.com
Status Recruiting
Phase Phase 2
Start date December 2012
Completion date June 2017
View Details

Clinical Trial Summary

A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast Cancer (MBC) patients, to evaluate the safety profile of this PM01183 to analyze the pharmacokinetics (PK) and PK/PD (pharmacokinetic/pharmacodynamic) correlations and to evaluate the pharmacogenomic (PGx) expression profile in tumor samples.


Clinical Trial Description

A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer to assess the antitumor activity of PM01183 in terms of overall response rate (ORR), duration of response (DR),clinical benefit [ORR or stable disease lasting over three months (SD > 3 months)], progression free survival (PFS), and one-year overall survival (1y-OS) and to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in MBC patients, to explore the activity of PM01183 in specific breast cancer subpopulations according to hormonal receptor status, HER-2 overexpression, number and/or type of prior therapies, or according to other available histological/molecular classifications, to evaluate the safety profile of this PM01183 administration schedule [Day 1 every three weeks (q3wk)] in this patient population, to analyze the pharmacokinetics (PK) of PM01183 in this patient population, to explore PK/PD (pharmacokinetic/ pharmacodynamic) correlations, if applicable and to evaluate the pharmacogenomic (PGx) expression profile of selected putative markers potentially predictive of response to PM01183, in tissues from archived tumor samples.


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Clinical Trial Details
See also
Status Clinical Trial Phase
 Not yet recruiting NCT02831426 - Pre-pectoral Breast Reconstruction PART 2 Phase 3
 Not yet recruiting NCT00960544 - Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism Phase 2
 Not yet recruiting NCT02779855 - Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Phase 1/Phase 2
 Not yet recruiting NCT02830685 - Pre-pectoral Breast Reconstruction PART 1 Phase 3
 Not yet recruiting NCT02784730 - Iterative PICC Placement Versus Long Term Device (PAC) in Oncology Phase 3
 Recruiting NCT02562118 - Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer Phase 1/Phase 2
 Recruiting NCT02565017 - Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System N/A
 Recruiting NCT02560818 - Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer N/A
 Recruiting NCT02466737 - Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery N/A
 Recruiting NCT02630368 - A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) Phase 1/Phase 2
 Recruiting NCT02547961 - Chimeric Antigen Receptor-Modified T Cells for Breast Cancer Phase 1/Phase 2
 Recruiting NCT02556684 - Breast-Specific Gamma Imaging and Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy N/A
 Recruiting NCT02239601 - Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms? N/A
 Recruiting NCT02759549 - Fatigue in Breast Cancer Patients Undergoing Radiotherapy-eSMART-MH N/A
 Recruiting NCT02547987 - Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer Phase 2
 Recruiting NCT02541370 - Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 Phase 1
 Recruiting NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
 Recruiting NCT02577627 - Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC N/A
 Recruiting NCT02694796 - Impact of Web and Smartphone-based Physical Activity Program on Physical Activity Level 12 Months After a Balneotherapy N/A
 Recruiting NCT02439437 - Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain N/A